Stocks · News reference

Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Benefits, And No Serious Adverse Events From Its 15 mA, 77.5 Hz DIFS Deep-Brain Stimulation Platform, At 2026 NYC Neuromodulation Conference

Jun 16, 2026, 1:18 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jun 16, 2026, 1:18 PM
Checked: Jun 16, 2026, 1:25 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 3, 2026, 6:57 PMBenzinga Newsdesk
Nexalin shares are trading lower. The company reported exploratory ADAS-Cog data from its completed trial of the Gen-2 SYNC DIFS neurostimulation device in in mild Alzheimer’s disease.
NXL
BenzingaSep 3, 2026, 12:35 PMBenzinga Newsdesk
Nexalin Says Post Hoc ADAS-Cog Analysis Of Gen-2 SYNC Alzheimer's Trial Found 10 Of 20 Evaluable Active-Arm Patients Improved 4 Or More Points; Findings To Inform Planned U.S. Pilot Study
NXL
SEC EDGARSep 2, 2026, 8:50 PMSEC EDGAR
8-K filing — Nexalin Technology, Inc. (NXL)
Filed: 2026-09-02 AccNo: 0001829126-26-009659 Size: 191 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
NXL
BenzingaAug 27, 2026, 4:53 PMBenzinga Newsdesk
Nexalin Technology shares are trading lower after the company announced a 1-for-30 reverse stock split.
NXL